Jazz took a step forward with the Chimerix acquisition that should further diversify its revenue base. Read why JAZZ stock is ...

Sun Pharmaceutical Industries Ltd. posted a mixed fourth quarter on Thursday and announced a softer-than-expected financial ...

JB Chemicals & Pharmaceuticals focuses on lozenges in CDM business, with minimal impact expected from US policy changes.

Emcure’s domestic business grew by 24.8% YoY in Q4FY25 led by its women’s health and cardio franchises and dermatology ...

Emcure Pharmaceuticals reported a 63% surge in net profit for Q1 2025, reaching Rs 197 crore, compared to Rs 121 crore in the ...

Emcure Pharma reported a 63% Y-o-Y jump in Q4 net profit to ₹197.2 crore, driven by strong domestic and international ...

Pune-headquartered pharma company Emcure Pharmaceuticals on Thursday reported that its Profit After Tax or net profit in the ...

Royalty Pharma reported 12% growth in Q1 royalty receipts, driven by Vertex, GSK, and Roche. Read why RPRX stock is a Buy.

Pune-headquartered Emcure Pharmaceuticals plans to expand its ... The revenue growth was driven by 24.8% growth in its domestic business, and 15.6% growth in its international business, Mehta ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A ...

Emcure Pharmaceuticals today announced strong performance across both its domestic and international businesses.

Emcure Pharma achieves robust Q4FY25 performance with 19% revenue growth and 63% profit after tax growth: Our Bureau, Mumbai Friday, May 23, 2025, 13:45 Hrs [IST] Emcure Pharma ha ...